drugset / Trial / NCT07115082
Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency
Non-randomizedParallel-groupSingle-blindTreatment
Summary
There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of human Amniotic mesenchymal stem cells (hA-MSCs) therapy in women suffering from POI.
Timeline
- Start
- 2024-10-15
- Primary completion
- 2025-12
- Completion
- 2026-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hA-MSCs | Unknown | 1e+06 cells/kg | Intravenous |
| Background | cyproterone acetate | Small molecule | 1 mg | Oral |
| Background | estradiol valerate | Unknown | 2 mg | Oral |